The public offering was led by Perceptive Advisors and Nantahala Capital, with participation from other new institutional biotech investors. Company CEO George Magrath and board chairman Cam Gallagher ...

Opus Genetics announces $20 million public offering and $1.5 million private placement for gene therapy development and operations. Opus Genetics, Inc., a clinical-stage biotechnology company ...

For companies seeking to raise capital without the complexities and costs of a public offering, Regulation D under the ...

The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today announced it has entered into a securities ...

QXO, Inc. (NYSE: QXO) (the "Company" or "QXO") today announced that it has entered into purchase agreements with certain ...

The offer and sale of the securities in the private placement as described above are being made in a transaction not involving a public offering and the securities have not been registered under ...

Despite a successful initial public offering, the reliance on concurrent private placements may indicate a lack of confidence from the public market, potentially signaling weaker investor sentiment.

Warrants to be issued as part of the public offering and concurrent private placement could bring in up to $21.4 million of additional capital 30 days following the release of OPGx-BEST1 DUO-1001 ...